TG Therapeutics Inc

NASDAQ:TGTX 4:00:00 PM EDT

32.04

+0.05 (+0.16%)

7:06:32 PM EDT: $32.04 0.00 (0.00%)

Market Cap (Intraday)	5.08B
Current PE	84.09
Forward PE	42.16
2yr Forward PE	18.63

See more stats

Estimates Current Quarter

Revenue	$152.25 Million
Adjusted EPS	$0.22

See more estimates

10-Day MA	$31.70
50-Day MA	$32.28
200-Day MA	$34.37

See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560

United States of America

Phone: +1.212.554.4484

Number of Employees: 338

http://www.tgtherapeutics.com

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.